科学文献

我们与学术机构开展合作研究,以评估我们的管线产品。以下是发表的相关文献。

年:

Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents

Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, Martin TG, Suvannasankha A, De Braganca KC, Corsale C, Schecter JM, Varsos H, Deraedt W, Wang L, Vogel M, Roccia T, Xu X, Mistry P, Zudaire E, Akram M, Nesheiwat T, Pacaud L, Avivi I, San-Miguel J

Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

Costa LJ, Hari P, Berdeja JG, De Stefano V, Gay F, Hooper B, Bartlett M, Haltner A, Rosta E, Kumar S, Martin T, Mateos MV, Moreau P, Usmani SZ, Olyslager Y, Schecter JM, Roccia T, Garrett A, Lee S, Nesheiwat T, Pacaud L, Zhou C, Samjoo IA, Lin Y, Diels J, Valluri S, Weisel K

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, Wei-Jun Fu, Jie Xu, Jie Liu, Shi-Wei Jin, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Hui Zhang, Ju Bai, Yan Xu, Han Zhu, Juan Du, Hua Jiang, Xiao-Hu Fan, Jian-Yong Li, Jian Hou, Zhu Chen, Wang-Gang Zhang, Jian-Qing Mi, Sai-Juan Chen, Ai-Li He

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Martin T, Usmani S, Berdeja J, Agha M, Cohen A, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi N, O’Donnell E, Stewart K, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S

close

您即将离开我们的网站

本网站使用Cookies来改善您的整体体验,让您下次访问网站时更加轻松快捷,为您带来更好的服务。具体内容请参阅 隐私政策 Cookie政策